Efficacy News and Research

RSS
ACP to provide physicians, patients with evidence-based recommendations for clinical problems

ACP to provide physicians, patients with evidence-based recommendations for clinical problems

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

NDSsi's ZeroWire Duo wireless Full HD video solution receives FDA clearance

NDSsi's ZeroWire Duo wireless Full HD video solution receives FDA clearance

NREF announces fellowship funding for 2010-2011

NREF announces fellowship funding for 2010-2011

GenVec's 2009 revenues down 8%: MicroStockProfit.com

GenVec's 2009 revenues down 8%: MicroStockProfit.com

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

Ampio Pharmaceuticals signs LOI to acquire DMI Biosciences

GUMC researchers awarded grant to discover and develop new smoking cessation drugs

GUMC researchers awarded grant to discover and develop new smoking cessation drugs

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Positive results from preclinical EP-302 program presented at AACR 2010

Positive results from preclinical EP-302 program presented at AACR 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.